Prevalence of and risk factors for pubic lipoma development in HIV-infected persons

Journal of Acquired Immune Deficiency Syndromes

Volumn 45, Issue 1, 2007, Pages 72-76

  Guaraldi, Giovanni ^a,e   Orlando, Gabriella ^a   Squillace, Nicola ^a   Roverato, Alberto ^a   De Fazio, Domenico ^b   Vandelli, Marcella ^c   Nardini, Giulia ^a   Beghetto, Barbara ^a   De Paola, Maria ^a   Esposito, Roberto ^a   Palella, Frank ^d  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b Casa di Cura Salus Hospital   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d NORTHWESTERN UNIVERSITY   (United States)

^e UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Fat redistribution; Lipoaccumulation; Lipodystrophy; Pubic lipoma

Indexed keywords

ADULT; ARTICLE; BODY MASS; CLINICAL FEATURE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ITALY; LIPODYSTROPHY; LIPOMA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OBESITY; OBSERVATIONAL STUDY; PHYSICAL EXAMINATION; PREVALENCE; PRIORITY JOURNAL; PUBIC LIPOMA; RISK FACTOR;

ADULT; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; FEMALE; GROIN; HIV; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PREVALENCE; RISK FACTORS;

EID: 34247570381     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31804a85b0     Document Type: Article

References (28)

1. van der Valk M, Bisschop PH, Romijn JA, et al. Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways. AIDS. 2001;15:2093-2100.
2. Thiebaut R, Daucourt V, Mercie P, et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidemiologie Clinique du Syndrome d'Immunodeficience Acquise en Aquitaine. Clin Infect Dis. 2000;31:1482-1487.
3. Saint-Marc T, Partisani M, Poizot-Martin I, et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS. 2000;14:37-49.
4. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS. 1999;13:1659-1667.
5. Polo R, Verdejo J, Martinez-Rodriguez S, et al. Lipoatrophy, fat accumulation, and mixed syndrome in protease inhibitor-naive HIV-infected patients. J Acquir Immune Defic Syndr. 2000;25:284-286.
6. Miller J, Carr A, Smith D, et al. Lipodystrophy following antiretroviral therapy of primary HIV infection. AIDS. 2000;14:2406-2407.
7. Miller J, Carr A, Emery S, et al. HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Med. 2003;4:293-301.
8. Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet. 2001;357:592-598.
9. Lichtenstein KADK, Armon C, Ward DJ, et al. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr. 2003;32:48-56.
10. Lichtenstein KA, Ward DJ, Moorman AC, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS. 2001;15:1389-1398.
11. Joly V, Flandre P, Meiffredy V, et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS. 2002;16:2447-2454.
12. Hendricks KM, Dong KR, Tang AM, et al. High-fiber diet in HIV-positive men is associated with lower risk of developing fat deposition. Am J Clin Nutr. 2003;78:790-795.
13. Hatano H, Miller KD, Yoder CP, et al. Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy. AIDS. 2000;14:1935-1942.
14. Goujard C, Boufassa F, Deveau C, et al. Incidence of clinical lipodystrophy in HIV-infected patients treated during primary infection. AIDS. 2001;15:282-284.
15. Gervasoni C, Ridolfo AL, Trifiro G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS. 1999;13:465-471.
16. Galli M, Cozzi-Lepri A, Ridolfo AL, et al. Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa Study. Arch Intern Med. 2002;162:2621-2628.
17. Carter VM, Hoy JF, Bailey M, et al. The prevalence of lipodystrophy in an ambulant HIV-infected population: it all depends on the definition. HIV Med. 2001;2:174-180.
18. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353:2093-2099.
19. Bogner JR, Vielhauer V, Beckmann RA, et al. Stavudine versus zidovudine and the development of lipodystrophy. J Acquir Immune Defic Syndr. 2001;27:237-244.
20. Galli M, Ridolfo AL, Adorni F, et al. Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr. 2002;29:21-31.
21. Carr A, Emery S, Law M, et al. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet. 2003;361:726-735.
22. Lauenroth-Mai E, Schlote F. HIV-associated lipodystrophy syndrome: LioN-HAART cohort: (lipodystrophy in patients on nucleoside-based HAART). Highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;31:253-255.
23. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12:F51-F58.
24. Lewis RH, Popescu M. Lipodystrophy: results of a data evaluation of patients receiving nelfinavir-containing combination therapy. J Acquir Immune Defic Syndr. 2000;23:355-356.
25. Guaraldi G, Squillace N, De Santis G, et al. Multidisciplinary approach to the treatment of metabolic and morphologic alterations of HIV-related lipodystrophy. HIV Clin Trials. 2006;7:97-106.
26. Edwards D. Introduction to Graphical Modelling. Springer, New York; 1995.
27. Galli M, Ridolfo AL, Adorni F, et al. Correlates of risk of adipose tissue alterations and their modifications over time in HIV-1-infected women treated with antiretroviral therapy. Antivir Ther. 2003;8:347-354.
28. Dolan SE, Hadigan C, Killilea KM, et al. Increased cardiovascular disease risk indices in HIV-infected women. J Acquir Immune Defic Syndr. 2005;39:44-54.